Kyowa Kirin Co 4151.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4151.T. It has been listed since 22 August 1949. In the fiscal year to 31 December 2025, it reported revenue of ¥496.83bn and net income of ¥67.04bn. At that date it held total assets of ¥1.11trn and shareholders' equity of ¥893.33bn.

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To. The firm operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of pharmaceuticals and industrial raw materials mainly for amino acid and nucleic acid related substances, as well as healthcare products.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Masashi MiyamotoChairman of the Board, Chief Executive Officer, Representative Director, since 2012¥204.0m
• Mr. Abdul MullickPresident, Chief Operating Officer, Representative Director, since 2023
• Mr. Motohiko KawaguchiManaging Executive Officer, Chief Financial Officer
• Mr. Yutaka OsawaVice President, Chief Compliance Officer, Representative Director, since 2013¥121.0m
• Dr. Takeyoshi YamashitaSenior Managing Executive Officer, Chief Medical Officer, Director, since 2017
• Mr. Hiroshi SonekawaManaging Executive Officer, Chief Director of Sales
• Mr. Yasuo FujiiManaging Executive Officer, Chief Strategy Officer
• Mr. Tadashi YamaguchiExecutive Officer, Director of Marketing in Main Sales Unit
• Ms. Shoko ItagakiExecutive Officer, Chief People Officer
• Mr. Fumihiko KanaiExecutive Officer
• Mr. Yuichi KawasakiExecutive Officer, Director of Product Strategy
• Mr. Toshiyuki KurataExecutive Officer, Chief Supply Chain Officer, Chief Director of Production

Overall

86

Environment

99

Social

99

Governance

59

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.